Therapy used today for anemia in congestive heart failure (CHF) and coronary heart disease (CHD)
Intravenous, IV iron therapy
Red Blood Cell, RBC transfusion
Erythropoiesis-stimulating agents (ESAs)
All three types of treatment have different health benefits and harms.
“The American College of Physicians, ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.”
“ACP recommends using a restrictive red blood cell transfusion strategy in hospitalized patients with coronary heart disease.”
“The effect of oral administration of iron and how it compares with IV (intravenously given) iron for treating anemic patients with heart disease is unknown.”
American College of Physicians (ACP) guideline
For oral administration efficacy and tolerance are central as well as easy administration.
The original OptiFer® heme iron supplements are considerably better taken up than oral non-heme iron and produce side-effects in the placebo range, as non-heme oral gives potentially therapy-destroying side-effects sooner or later.
Heme iron therapy is reasonably priced and much lower than for instance intravenous therapy in chronic cases. Side-effects will not ruin the therapy. Heme iron therapy has a much higher success rate due to tolerance than non-heme iron therapy.